- Discussion
- 10.1016/j.jad.2026.121668
Have a heart: Evidence for a suicide problem in cardiology.
- Aug 01, 2026
- Journal of affective disorders
- Phillip J Tully + 5 more +5
Publications from 2021 to 2026
Showing 10 of 2,326 papers
Have a heart: Evidence for a suicide problem in cardiology.
WCN26-381 Patients’ experiences and perspectives on sleep assessment and management in chronic kidney disease: A multicentre mixed-methods study
A Pilot Randomised Controlled Dose-Ranging Trial of Ant Venom Immunotherapy With and Without Delta-Inulin Adjuvant.
Jack Jumper ant (JJA) venom immunotherapy (VIT) is highly efficacious but the lowest effective dose is unknown. Delta-inulin adjuvant (Advax) is known to enhance honeybee VIT immunogenicity. This phase 1/2 single-blind, randomised controlled trial aimed to compare the efficacy and safety of JJA VIT with different doses of venom ± Advax. Adults aged 18-65 with a history of immediate systemic reaction (SR) to JJA stings were randomised to receive JJA VIT at a maintenance dose of 25 mcg or 50 mcg ± Advax; participants were blinded to treatment allocation. Primary outcomes were the response to sting challenges after 12 months and venom-specific IgE and IgG4 responses to treatment. Forty-nine of 50 screened subjects met inclusion criteria and were randomised; 44 started treatment (25 mcg n = 12; 25 mcg + Advax n = 13; 50mcg n = 12, 50 mcg + Advax n = 12). Subsequently, two withdrew due to SRs to treatment, and two withdrew due to unrelated factors. The higher JJA venom maintenance dose was associated with reduced likelihood of SRs (OR 0.53 (95% CI, 0.28-0.98)), while Advax did not have an effect (OR 1.17 (95% CI, 0.59-2.32)). Forty proceeded to sting challenge, with six developing SRs. There was no difference between groups for sting challenge outcome (p = 0.98), and the ORs for 25 mcg vs. 50 mcg venom dose (0.89, 95% CI, 0.38-2.09) and Advax vs. no Advax (0.99, 95% CI 0.42-2.33) indicated no effect. There were no differences between groups for venom sIgE (p = 0.78), sIgG4 (p = 0.25), sIgE/IgG4 ratio (p = 0.42), intradermal (p = 0.77), and basophil activation test (BAT) (p = 0.69) responses to treatment. Subjects with high baseline BAT sensitivity, which reduced markedly in response to treatment, were less likely to have a positive sting challenge (p = 0.006). Challenge outcomes were similar for all groups, with no significant difference found between 25 and 50 mcg maintenance dose or between treatment with and without Advax. Further research of low dose JJA VIT is warranted to confirm its efficacy and tolerability. NCT03066986.
Read moreIdentification of a Novel, Oncogenic and Targetable TPR::ABL2 Fusion Gene in T-Cell Acute Lymphoblastic Leukaemia.
ABL2 rearrangements represent a subtype of acute lymphoblastic leukaemia (ALL) associated with poor prognosis and survival. This study reports a high-risk T-cell ALL (T-ALL) case with a novel TPR::ABL2 gene fusion resulting from a chromosomal deletion. Overexpression of TPR::ABL2 in Ba/F3 cells promoted cytokine-independent growth, demonstrating its oncogenic nature. Both primary patient and Ba/F3 cells carrying TPR::ABL2 exhibited kinase activation and sensitivity to tyrosine kinase inhibitors (TKIs). This study expands the repertoire of ABL2 fusions identified in ALL and supports the incorporation of TKIs into T-ALL treatment regimens to improve outcomes for this subtype.
Read morePrecision sleep medicine for the aging population: Moving from device-centered to person-centered care.
Analgesic efficacy of the ultrasound-guided pericapsular nerve group (PENG) block for ambulatory hip arthroscopy: a randomized controlled double-blind trial.
Hip arthroscopy is an increasingly common outpatient surgical procedure where postoperative pain can be severe. Peripheral nerve blocks have been evaluated for analgesia following hip arthroscopy; however, there is no consensus on an optimal technique that provides effective local anesthetic-based postoperative analgesia without motor blockade. We hypothesized that the pericapsular nerve group (PENG) block would provide effective motor-sparing analgesia following ambulatory hip arthroscopy. We conducted a randomized placebo-controlled double-blind trial comparing an ultrasound-guided PENG block with 20 mL of 0.5% ropivacaine to a control with a sham injection. Our primary outcomes were cumulative opioid consumption (oral morphine equivalent) and quality of recovery (QoR-15) scores at 24 hours postoperatively. Secondary outcomes included pain, postoperative opioid consumption, time to first analgesic request, postanesthesia care unit (PACU) length of stay, and opioid and block-related side effects. 94 patients were included (47 per group). QoR was similar between groups at 24 hours as measured by the QoR-15 (range 0-150, higher scores indicate better recovery): mean SD 96.8±20.9 in the PENG group versus 101.0±20.9 in the control group (mean difference -4.2; adjusted p=0.414). Opioid consumption at 24 hours was also similar between groups. In adjusted analyses, the PENG group required less opioid analgesia in the PACU (mean difference -9.5 MME; p=0.039) and had a shorter PACU stay (mean difference -20.5 min; p=0.027). Pain scores at rest and on movement decreased over time in both groups, with no consistent differences in overall pain trajectories. Opioid consumption at 48 hours, opioid-related adverse effects and block-related complications were similar between groups. When administered preoperatively, the PENG block provides only modest early perioperative benefits without improving overall postoperative analgesia or QoR in patients undergoing ambulatory hip arthroscopy. Based on these findings, routine preoperative use of the PENG block for ambulatory hip arthroscopy cannot be recommended beyond standard multimodal analgesia, although it may be considered selectively to facilitate early PACU recovery in carefully chosen patients. The potential role of postoperative PENG block as a rescue intervention warrants further investigation. NCT03449680; https://clinicaltrials.gov/study/NCT03449680.
Read moreObesity Management and Cardiovascular Risk Reduction: from Tradition to Innovation
Macintyre’s Acute Pain Management
With a focus on practical acute pain management in the hospital setting, Macintyre’s Acute Pain Management: A Practical Guide provides health professionals with simple and practical information to help them manage adult patients with acute pain safely and effectively in both surgical and nonsurgical settings. Incorporating updated information for all medications and techniques, the sixth edition of this established text addresses the key issues in analgesic stewardship, including in the preadmission (where possible), admission and postdischarge phases of a patient’s care. Combining evidence-based information with practical guidelines and protocols, it offers vital knowledge on the management of acute pain in both surgical and nonsurgical patients, including in those with spinal cord injuries, burns, and selected medical illnesses. More complex issues are covered, such as treating the older patient, those with a substance use disorder, pregnant or lactating patients, patients with sleep-disordered breathing, and those with renal or hepatic impairment. The benefits and potential risks for analgesic medications as well as techniques are discussed, and strategies are outlined that aim to help mitigate patient harm, including after discharge from hospital. Macintyre’s Acute Pain Management: A Practical Guide is a valuable and reliable reference for the variety of professionals who will assess and manage patients with acute pain, including trainees in anaesthesia and pain medicine programmes, certified registered nurse anaesthetists, and anaesthesia assistants, junior medical staff and nurses, and undergraduate/graduate entry level students in medical, nursing, pharmacy and other health professional courses.
Read moreGenomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis
Impact of Dedicated Cardiologist Input on the Rate of Prescription of Guideline-Directed Medical Therapy After Coronary Artery Bypass Graft Surgery-A Retrospective Cohort Study (The ROSS Effect).